Does Epivir (lamivudine) cause side effects?
Epivir (lamivudine) is an antiviral medication used to treat HIV infection and hepatitis B virus (HBV) infection. It also is used off-label to prevent HIV among individuals accidentally exposed to HIV.
Common side effects of Epivir include
- fever,
- abdominal pain,
- weight loss,
- nausea,
- vomiting,
- diarrhea,
- hair loss, and
- difficulty sleeping.
Serious side effects of Epivir include
- pancreatitis,
- liver failure,
- metabolic disturbance (lactic acidosis),
- decreased blood cells,
- muscle pain,
- weakness, and
- nerve damage in the extremities (peripheral neuropathy).
- Symptoms of peripheral neuropathy are tingling, numbness and pain in the feet or hands.
Drug interactions of Epivir include trimethoprim/sulfamethoxazole, which increases the concentration of Epivir in the body. Zalcitabine and Epivir may interfere with the activity of each other.
Use of Epivir during pregnancy has not been adequately evaluated. It is unknown if Epivir is secreted in breast milk. HIV infected mothers should not breastfeed because of the potential risk of transmitting HIV to an infant that is not infected.
What are the important side effects of Epivir (lamivudine)?
The most severe side effects of lamivudine are:
- pancreatitis,
- liver failure,
- metabolic disturbance (lactic acidosis),
- a decrease in blood cells,
- muscle pain,
- weakness, and
- nerve damage in the extremities (peripheral neuropathy). Symptoms of peripheral neuropathy are tingling, numbness and pain in the feet or hands.
Other important side effects are
- fever,
- abdominal pain,
- weight loss,
- nausea,
- vomiting,
- diarrhea,
- hair loss, and
- difficulty sleeping.
Epivir (lamivudine) side effects list for healthcare professionals
The following adverse reactions are discussed in other sections of the labeling:
- Exacerbations of hepatitis B.
- Lactic acidosis and severe hepatomegaly with steatosis.
- Hepatic decompensation in patients co-infected with HIV-1 and hepatitis C.
- Pancreatitis.
- Immune reconstitution syndrome.
Clinical Trials Experience
Clinical Trials Experience In Adult Subjects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety profile of Epivir in adults is primarily based on 3,568 HIV-1-infected subjects in 7 clinical trials.
The most common adverse reactions are
Selected clinical adverse reactions in greater than or equal to 5% of subjects during therapy with Epivir 150 mg twice daily plus Retrovir 200 mg 3 times daily for up to 24 weeks are listed in Table 3.
Table 3: Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency) in Four Controlled Clinical Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002)
Adverse Reaction | Epivir 150 mg Twice Daily plus Retrovir (n = 251) | Retrovira (n = 230) |
Body as a Whole | ||
Headache | 35% | 27% |
Malaise & fatigue | 27% | 23% |
Fever or chills | 10% | 12% |
Digestive | ||
Nausea | 33% | 29% |
Diarrhea | 18% | 22% |
Nausea & vomiting | 13% | 12% |
Anorexia and/or decreased appetite | 10% | 7% |
Abdominal pain | 9% | 11% |
Abdominal cramps | 6% | 3% |
Dyspepsia | 5% | 5% |
Nervous System | ||
Neuropathy | 12% | 10% |
Insomnia & other sleep disorders | 11% | 7% |
Dizziness | 10% | 4% |
Depressive disorders | 9% | 4% |
Respiratory | ||
Nasal signs & symptoms | 20% | 11% |
Cough | 18% | 13% |
Skin | ||
Skin rashes | 9% | 6% |
Musculoskeletal | ||
Musculoskeletal pain | 12% | 10% |
Myalgia | 8% | 6% |
Arthralgia | 5% | 5% |
a Either zidovudine monotherapy or zidovudine in combination with zalcitabine. |
Pancreatitis
Pancreatitis was observed in 9 out of 2,613 adult subjects (0.3%) who received Epivir in controlled clinical trials
- EPV20001,
- NUCA3001,
- NUCB3001,
- NUCA3002,
- NUCB3002, and
- NUCB3007.
Epivir 300 mg Once Daily
The types and frequencies of clinical adverse reactions reported in subjects receiving Epivir 300 mg once daily or Epivir 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) for 48 weeks were similar.
Selected laboratory abnormalities observed during therapy are summarized in Table 4.
Table 4: Frequencies of Selected Grade 3-4 Laboratory Abnormalities in Adults in Four 24-Week Surrogate Endpoint Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002) and a Clinical Endpoint Trial (NUCB3007)
Test (Threshold Level) | 24-Week Surrogate Endpoint Trialsa | Clinical Endpoint Triala | ||
Epivir plus Retrovir | Retrovirb | Epivir plus Current Therapyc | Placebo plus Current Therapyc | |
Absolute neutrophil count (<750/mm³) | 7.2% | 5.4% | 15% | 13% |
Hemoglobin (<8.0 g/dL) | 2.9% | 1.8% | 2.2% | 3.4% |
Platelets (<50,000/mm³) | 0.4% | 1.3% | 2.8% | 3.8% |
ALT (>5.0 x ULN) | 3.7% | 3.6% | 3.8% | 1.9% |
AST (>5.0 x ULN) | 1.7% | 1.8% | 4.0% | 2.1% |
Bilirubin (>2.5 x ULN) | 0.8% | 0.4% | ND | ND |
Amylase (>2.0 x ULN) | 4.2% | 1.5% | 2.2% | 1.1% |
a The median duration on study was 12 months. b Either zidovudine monotherapy or zidovudine in combination with zalcitabine. c Current therapy was either zidovudine, zidovudine plus didanosine, or zidovudine plus zalcitabine. ULN = Upper limit of normal. ND = Not done. |
The frequencies of selected laboratory abnormalities reported in subjects receiving Epivir 300 mg once daily or Epivir 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) were similar.
Clinical Trials Experience In Pediatric Subjects
Epivir oral solution has been studied in 638 pediatric subjects aged 3 months to 18 years in 3 clinical trials.
Selected clinical adverse reactions and physical findings with a greater than or equal to 5% frequency during therapy with Epivir 4 mg per kg twice daily plus Retrovir 160 mg per m² 3 times daily in therapy-naive (less than or equal to 56 days of antiRetroviral therapy) pediatric subjects are listed in Table 5.
Table 5: Selected Clinical Adverse Reactions and Physical Findings (Greater than or Equal to 5% Frequency) in Pediatric Subjects in Trial ACTG300
Adverse Reaction | Epivir plus Retrovir (n = 236) | Didanosine (n = 235) |
Body as a Whole | ||
Fever | 25% | 32% |
Digestive | ||
Hepatomegaly | 11% | 11% |
Nausea & vomiting | 8% | 7% |
Diarrhea | 8% | 6% |
Stomatitis | 6% | 12% |
Splenomegaly | 5% | 8% |
Respiratory | ||
Cough | 15% | 18% |
Abnormal breath sounds/wheezing | 7% | 9% |
Ear, Nose, and Throat | ||
Signs or symptoms of earsa | 7% | 6% |
Nasal discharge or congestion | 8% | 11% |
Other | ||
Skin rashes | 12% | 14% |
Lymphadenopathy | 9% | 11% |
a Includes pain, discharge, erythema, or swelling of an ear. |
Pancreatitis
- Pancreatitis, which has been fatal in some cases, has been observed in antiRetroviral nucleoside-experienced pediatric subjects receiving Epivir alone or in combination with other antiRetroviral agents.
- In an open-label dose-escalation trial (NUCA2002), 14 subjects (14%) developed pancreatitis while receiving monotherapy with Epivir. Three of these subjects died of complications of pancreatitis.
- In a second open-label trial (NUCA2005), 12 subjects (18%) developed pancreatitis.
- In Trial ACTG300, pancreatitis was not observed in 236 subjects randomized to Epivir plus Retrovir.
- Pancreatitis was observed in 1 subject in this trial who received open-label Epivir in combination with Retrovir and ritonavir following discontinuation of didanosine monotherapy.
Paresthesias And Peripheral Neuropathies
Paresthesias and peripheral neuropathies were reported in 15 subjects (15%) in Trial NUCA2002, 6 subjects (9%) in Trial NUCA2005, and 2 subjects (less than 1%) in Trial ACTG300.
Selected laboratory abnormalities experienced by therapy-naive (less than or equal to 56 days of antiRetroviral therapy) pediatric subjects are listed in Table 6.
Table 6: Frequencies of Selected Grade 3-4 Laboratory Abnormalities in Pediatric Subjects in Trial ACTG300
Test (Threshold Level) | Epivir plus Retrovir | Didanosine |
Absolute neutrophil count (<400/mm ) | 8% | 3% |
Hemoglobin (<7.0 g/dL) | 4% | 2% |
Platelets (<50,000/mm³) | 1% | 3% |
ALT (>10 x ULN) | 1% | 3% |
AST (>10 x ULN) | 2% | 4% |
Lipase (>2.5 x ULN) | 3% | 3% |
Total Amylase (>2.5 x ULN) | 3% | 3% |
ULN = Upper limit of normal. |
Pediatric Subjects Once-Daily Versus Twice-Daily Dosing (COL105677)
- The safety of once-daily compared with twice-daily dosing of Epivir was assessed in the ARROW trial.
- Primary safety assessment in the ARROW trial was based on Grade 3 and Grade 4 adverse events.
- The frequency of Grade 3 and 4 adverse events was similar among subjects randomized to once-daily dosing compared with subjects randomized to twice-daily dosing.
- One event of Grade 4 hepatitis in the once-daily cohort was considered as uncertain causality by the investigator and all other Grade 3 or 4 adverse events were considered not related by the investigator.
Neonates
- Limited short-term safety information is available from 2 small, uncontrolled trials in South Africa in neonates receiving lamivudine with or without zidovudine for the first week of life following maternal treatment starting at Week 38 or 36 of gestation.
- Selected adverse reactions reported in these neonates included
- increased liver function tests,
- anemia,
- diarrhea,
- electrolyte disturbances,
- hypoglycemia,
- jaundice and hepatomegaly,
- rash,
- respiratory infections, and
- sepsis; 3 neonates died (1 from gastroenteritis with acidosis and convulsions, 1 from traumatic injury, and 1 from unknown causes).
- Two other nonfatal gastroenteritis or diarrhea cases were reported, including 1 with convulsions; 1 infant had transient renal insufficiency associated with dehydration.
- The absence of control groups limits assessments of causality, but it should be assumed that perinatally exposed infants may be at risk for adverse reactions comparable to those reported in pediatric and adult HIV-1-infected patients treated with lamivudine-containing combination regimens.
- Long-term effects of in utero and infant lamivudine exposure are not known.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Epivir. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to lamivudine.
Body as a Whole
Redistribution/accumulation of body fat.
Endocrine and Metabolic
General
Weakness. Hemic and Lymphatic Anemia (including pure red cell aplasia and severe anemias progressing on therapy).
Hepatic and Pancreatic
Lactic acidosis and hepatic steatosis, posttreatment exacerbations of hepatitis B.
Hypersensitivity
Musculoskeletal
Muscle weakness, CPK elevation, rhabdomyolysis. Skin Alopecia, pruritus.
What drugs interact with Epivir (lamivudine)?
Drugs Inhibiting Organic Cation Transporters
Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim).
No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.
Sorbitol
Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine.
Summary
Epivir (lamivudine) is an antiviral medication used to treat HIV infection and hepatitis B virus (HBV) infection. It also is used off-label to prevent HIV among individuals accidentally exposed to HIV. Common side effects of Epivir include fever, abdominal pain, weight loss, nausea, vomiting, diarrhea, hair loss, and difficulty sleeping. Use of Epivir during pregnancy has not been adequately evaluated. It is unknown if Epivir is secreted in breast milk. HIV infected mothers should not breastfeed because of the potential risk of transmitting HIV to an infant that is not infected.
Multimedia: Slideshows, Images & Quizzes
-
Liver Health: 14 Best and Worst Foods for Your Liver
Get some simple diet tips to keep your liver healthy, including the best veggies to keep disease away and some snacks you'll want...
-
What Are HIV & AIDS? Symptoms, Treatment, and Prevention
HIV, or human immunodeficiency virus, causes acquired immunodeficiency syndrome, or AIDS. Learn about HIV symptoms, HIV test, HIV...
-
HIV AIDS: Myths and Facts
What is HIV versus AIDS? What are the symptoms of HIV? Is there an HIV cure? Discover myths and facts about living with HIV/AIDS....
-
Picture of HIV Lipodystrophy
HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on...
-
HIV & AIDS Quiz: HIV Testing & Symptoms
Now, more than ever, you should know about HIV/AIDS, especially its causes, symptoms treatments, and complications. Take the...
-
Picture of Hepatitis B
Inflammation of the liver due to the hepatitis B virus (HBV), once thought to be passed only through blood products. See a...
Related Disease Conditions
-
HIV Early Signs and Stages
HIV (human immunodeficiency virus) weakens your immune system. Some people with HIV don’t have any symptoms, but those that do may experience mononucleosis-like or flu-like symptoms. There are 3 stages of HIV.
-
HIV and AIDS
Second Source article from WebMD
-
Is Hepatitis B Contagious?
Hepatitis B is a type of liver infection. Hepatitis B is spread through person-to-person contact or through personal items like razors, toothbrushes, etc. Symptoms of hepatitis B include fever, yellowish skin (jaundice), dark urine, fatigue, nausea, and vomiting. There is no drug to cure hepatitis B; however, there is a hepatitis B vaccine available.
-
Hepatitis B (HBV, Hep B)
The hepatitis B virus (HBV, hep B) is a unique, coated DNA virus belonging to the Hepadnaviridae family of viruses. The course of the virus is determined primarily by the age at which the infection is acquired and the interaction between the virus and the body's immune system. Successful treatment is associated with a reduction in liver injury and fibrosis (scarring), a decreased likelihood of developing cirrhosis and its complications, including liver cancer, and a prolonged survival.
-
HIV vs. AIDS
Human immunodeficiency virus causes HIV infection. Acquired immunodeficiency syndrome (AIDS) is a condition that results after HIV has extensively damaged a person's immune system. Risk factors for HIV and AIDS include use of contaminated needles or syringes, unprotected sex, STDs, receiving a blood transfusion prior to 1985 in the United States, having many sex partners, and transmission from a mother to her child.
-
Can HIV be Cured Naturally?
HIV stands for human immunodeficiency virus. If someone has HIV it means that they have been diagnosed with the HIV infection. AIDS (acquired immune deficiency syndrome); however, is the most advanced or final stage of the HIV infection. It is important to get tested for HIV in the early stages of infection to minimize the damage to the immune system. Successful treatment aims to reduce HIV load to a level that is harmless to the body.
-
HIV Medications List and Drug Charts
The ultimate goal of HIV treatment is getting the viral load down below detectable levels. As long as those viral load and antibody levels are below a proscribed range, people with HIV can stave off AIDS and other serious symptoms. Antiviral treatment options usually include combinations of two NRTIs, often referred to as "nucs," and a third drug, typically being a boosted protease inhibitor, a NNRTI, often called "non-nucs," and integrase strand transfer inhibitors.
-
HIV/AIDS Infection Transmission and Prevention
HIV (human immunodeficiency virus) is spread through contact with genital fluids or blood of an infected person. The spread of HIV can occur when these secretions come in contact with tissues such as those lining the vagina, anal area, mouth, eyes (the mucus membranes), or with a break in the skin, such as from a cut or puncture by a needle.
-
HIV/AIDS Testing: Diagnosis and Monitoring
HIV/AIDS diagnosis and monitoring have come a long way from the days when a diagnosis was a death sentence. Crucial parts of the effective treatment regimens developed in the last 40 years are consistent monitoring of the viral load (the amount of virus in the blood), and the immune cell count, which function as biological markers of the disease’s progression. Doctors also must test for drug resistance.
-
HIV/AIDS Facts: What Is HIV?
HIV (human immunodeficiency virus) is the precursor infection to AIDS (acquired immunodeficiency syndrome). HIV is transmitted through blood and genital secretions; most people get it through sexual contact or sharing needles for illegal IV drug use. HIV can be controlled by a strict drug regimen, but left unchecked, it leads to AIDS. In AIDS, the immune system collapses and the body falls prey to secondary, opportunistic infections and cancers that typically kill the person.
-
What Are the Side Effects of HIV Medications?
It’s important to know the potential side effects of all the drugs you take to control your HIV infection, as well as potential drug interactions. All of the NNRTIs (nonnucleoside analogue reverse transcriptase inhibitors), for example, are associated with important drug-drug interactions so they must be used with caution in patients on other medications. Learn more about the side effects of the drugs in standard treatment regimens.
-
HIV Life Expectancy and Long-term Outlook
With early diagnosis and proper treatment, people with HIV can live a healthy and long life. There is no generalized definitive period for which a person with HIV can live.
-
When should you start HIV medication?
Nearly everyone who is infected with HIV (human immunodeficiency virus) should start antiviral medication therapy as soon as they are diagnosed. Older guidelines recommended delaying treatment to help reduce the potential for drug side effects and viral resistance to treatment. Current thinking theorizes that early treatment may preserve more of the body's immune function.
Treatment & Diagnosis
- HIV-AIDS FAQs
- HIV Treatment, Medications, and Prevention
- HIV Urine Test Approved
- HIV Treatment - To Interrupt or Not
- Unprotected Sex Between HIV-Infected Partners: What's the Harm?
- HIV Transmission and Progression to AIDS Continues
- Physical and Biochemical Changes in HIV Disease
- Babies On The Breast Of HIV Moms
- HIV / AIDS Conference Update 2005 - Index
- Retrovirus & Opportunistic Infections Part II
- Can You Be Allergic to Ceclor for Hepatitis B?
- Can HIV Cause Kaposi's Sarcoma?
- Do You Need Antiretroviral Therapy for HIV with No Symptoms?
- Does HIV Cause Colorectal Cancer?
- Does Anti-Retroviral Therapy for HIV Cause Diabetes?
- How Long Should You Wait to Get an HIV Test?
- What Liver Problems Does HIV Cause?
- Can You Treat Hepatitis B With Aids Drug Lamivudine?
- Does Circumcision Prevent HIV and AIDS?
- Does Hepatitis B Cause Liver Cancer?
- HIV Infection Facts, History, Causes, and Risk Factors
- HIV Tests, Symptoms, Signs, and Stages of Infection
- Baby "Cured" of HIV Infection
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.